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Background: Individuals with a personal or family history of cancer, can opt for genetic counseling and DNA-
testing. Approximately 25% of these individuals experience clinically relevant levels of psychosocial distress, depression
and/or anxiety after counseling. These problems are frequently left undetected by genetic counselors. The aim of this
study is to evaluate the efficacy of a cancer genetics-specific screening questionnaire for psychosocial problems, the
‘Psychosocial Aspects of Hereditary Cancer (PAHC) questionnaire’ together with the Distress Thermometer, in: (1)
facilitating personalized counselor-counselee communication; (2) increasing counselors’ awareness of their counselees’
psychosocial problems; and (3) facilitating the management of psychosocial problems during and after genetic counseling.
Methods: This multicenter, randomized controlled trial will include 264 individuals undergoing cancer genetic counseling
in two family cancer clinics in the Netherlands. Participants will be randomized to either: (1) an intervention group that
completes the PAHC questionnaire, the results of which are made available to the genetic counselor prior to the
counseling session; or (2) a control group that completes the PAHC questionnaire, but without feedback being given to
the genetic counselor. The genetic counseling sessions will be audiotaped for content analysis. Additionally, study
participants will be asked to complete questionnaires at baseline, three weeks after the initial counseling session, and four
months after a telephone follow-up counseling session. The genetic counselors will be asked to complete questionnaires
at the start of and at completion of the study, as well as a checklist directly after each counseling session. The
questionnaires/checklists of the study include items on communication during genetic counseling, counselor awareness
of their clients’ psychosocial problems, the (perceived) need for professional psychosocial support, cancer worries, general
distress, specific psychosocial problems, satisfaction with care received, and experience using the PAHC questionnaire.
Discussion: This study will provide empirical evidence regarding the efficacy of a relatively brief psychosocial screening
questionnaire in terms of facilitating personalized communication, increasing counselors’ awareness, and optimizing
management of psychosocial problems in the cancer genetic counseling setting.
Trial registration: This study is registered at the Netherlands Trial Register (NTR3205) and ClinicalTrials.gov (NCT01562431).
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Genetic counseling is offered to individuals who are at
high risk of carrying a cancer gene mutation and who are
at high risk of developing hereditary cancer. Factors re-
lated to hereditary cancer are: a cancer diagnosis at a
young age, multiple relatives with a similar cancer diagno-
sis or a specific combination of cancers and a proven gene
mutation in the family [1]. Reviews of previous studies in-
dicate that, on average, genetic counseling does not have
adverse psychological effects (i.e., depression, anxiety, dis-
tress). However, approximately 25% of high risk individuals
experience clinically relevant adverse psychosocial effects
after counseling [2-13].
It has been estimated that approximately one-third of
counseless have some level of unmet need for psycho-
social services in relation to genetic counseling [14,15].
This is not entirely surprising, in that genetic counselors
focus primarily on gathering and communicating bio-
medical information, and often have a ‘teaching’ commu-
nication style [16]. This creates a situation where there
is less time available to discuss potentially relevant psy-
chosocial issues.
Patient reported outcome (PRO) measures have been
used in a range of health care settings as a tool to im-
prove communication between patients and their health
care providers about relevant physical and psychosocial
health problems [17-20]. Facilitating such communica-
tion has been hypothesized to have a cascade of effects,
including improved provider awareness of their patients’
problems, improved patient care and management, in-
cluding appropriate referrals, and ultimately, improved
health outcomes [21-24].
Recently, we developed a psychosocial screening ques-
tionnaire specifically for the clinical cancer genetics setting,
the Psychosocial Aspects of Hereditary Cancer (PAHC)
questionnaire [25]. The PAHC questionnaire comprises:
(1) 26 items organized into 6 problem domains (i.e., her-
editary predisposition, family- and social issues, practical
issues, general emotional issues, cancer-specific issues,
and, for those who have children, children-specific issues),
with response options ranging from 1 (‘not at all’) to 4
(‘very much’); (2) a question, per problem domain, about
the desire to talk to a specialized psychosocial health pro-
fessional; and (3) the Distress Thermometer (DT), a single
item visual analogue scale ranging from 0–10, with 0
representing ‘no distress,’ and 10 ‘severe distress’ [26].
The aim of this randomized, controlled trial is to eva-
luate the efficacy of the PAHC questionnaire when used
routinely in daily clinical cancer genetics practice in: (1) fa-
cilitating communication during genetic counseling ses-
sions about relevant psychosocial issues; (2) increasing
genetic counselors’ awareness of the psychosocial problems
of their counselees; and (3) facilitating the appropriate
management of these cancer genetic-specific psychosocialproblems. Specifically, our primary research hypotheses
are that the use of the PAHC questionnaire during genetic
counseling will:
(1) increase significantly the number of psychosocial
issues discussed during genetic counseling sessions;
(2) increase significantly the genetic counselors’
awareness of the psychosocial problems experienced
by their counselees; and
(3) improve significantly the management of cancer
genetic-specific psychosocial problems as evidenced
by the referrals to psychosocial care and/or to
sources of information about psychosocial issues.
Additionally, we hypothesize that the routine use of
the PAHC questionnaire will:
(4) increase significantly the number of discussed issues
initiated by the counselor;
(5) increase significantly counselees’ satisfaction with
the counseling process;
(6) decrease significantly counselees’ levels of cancer
worry and distress during and after the genetic
counseling process;
(7) decrease significantly the cancer genetic-specific
problems experienced by the counselee after the
genetic counseling process; and
(8) not increase significantly the total duration of the
genetic counseling session.
Methods/design
This is a prospective, multicenter, randomized controlled
trial in which participants will be randomly allocated to:
(1) an intervention group that completes the PAHC ques-
tionnaire prior to genetic counseling, the results of which
are provided to the genetic counselor; or (2) a control
group that completes the PAHC questionnaire, without
feedback being given to the genetic counselor. The study
consists of two phases. In the first part of the study, the
focus is on the efficacy of the intervention during the first
face-to-face genetic counseling session. The second phase
of the study is concerned with the efficacy of the inter-
vention during a telephone follow-up held approximately
4 weeks after DNA-test results are disclosed in a final
face-to-face counseling session.
The primary outcome measures are counselor-counselee
communication about psychosocial problems, counselors’
awareness of their counselees’ psychosocial problems, and
improved management of those problems. Secondary out-
comes include satisfaction with the counseling process,
cancer worries, psychological distress, and prevalence of
psychosocial problems. The design of the study and the
anticipated flow of participants are displayed graphically in
Figure 1.
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Figure 1 Design of the trial.
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lows the CONSORT guidelines [27] and is registered at the
Netherlands Trial Register (NTR3205) and ClinicalTrials.
gov (NCT01562431).
Study sample
The study sample will be composed of 264 counselees
who request genetic counseling at either The Netherlands
Cancer Institute in Amsterdam or the University Medical
Center Utrecht. Counselees will be excluded from the
study if they are younger than 18 years of age, do not have
basic fluency in the Dutch language or are participating in
another study that would interfere with the current study.
Recruitment and randomization
All eligible counselees will receive an invitation letter from
the family cancer clinic, an informed consent form, a base-
line questionnaire, and a return envelope three weeks
before their first counseling session. Upon returning
the completed informed consent form and the baselinequestionnaire, we will randomize the participants on a
1:1 basis to either the intervention group or the control
group. The minimization method will be used to balance
the intervention and control group for each counselor in
terms of gender and the cancer syndrome for which gen-
etic counseling is requested [28]. Neither the counselees
nor the counselors will be (or can be) blinded to group
assigment.
Intervention group procedure
Within the Netherlands, individuals seeking cancer gen-
etic counseling routinely undergo a first consultation with
a genetic counselor or a clinical geneticist and, when opt-
ing for a DNA-test, a final counseling session during
which the DNA-test results are disclosed to the counselee.
If indicated, screening recommendations for the patient
and relatives are discussed within these sessions. The
study intervention will take place within this standardized
process, at the time of the first face-to-face genetic coun-
seling session (phase I), and by telephone 4 weeks after
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participants in the intervention group will be asked to
complete the PAHC questionnaire either via the internet
or, if preferred, by mail shortly before the face-to-face and
the telephone follow-up counseling sessions. The coun-
selee’s responses to the PAHC questionnaire will be made
available to the genetic counselor prior to the counseling
sessions.
The PAHC questionnaire consists of 26 questions ad-
dressing psychosocial problems and worries that are spe-
cifically relevant to counselees within the cancer genetics
counseling and testing setting. The content of the PAHC
questionnaire is organized into the following six domains:
(1) hereditary predisposition; (2) family- and social is-
sues; (3) practical issues; (4) general emotional issues;
(5) cancer-specific issues; and, for those who have children
6) children-specific issues. The number of items per do-
main varies between 2 and 7. All 26 items are scored on a
4-point, Likert-type scale ranging from 1 (“not at all”) to 4
(“very much”). The PAHC questionnaire is supplemented
by the Distress Thermometer (DT), a visual analogue scale
ranging from 0–10 (no distress-severe distress). The time-
frame of the PAHC questionnaire and the DT is the previ-
ous week. Per problem domain assessed by the PAHC
questionnaire, the respondent is asked to indicate whether
(s)he would like to receive professional psychosocial
support [25].
The results of the PAHC questionnaire + DT will be
printed and attached to the counselee’s medical record
so that they are available to the genetic counselor prior
to the relevant counseling session (face-to-face in phase
I and telephone-based in phase II). To facilitate the gen-
etic counselor’s rapid review of the questionnaire output,
all problem domains for which the counselee responds
“quite a bit” or “very much” to at least one item are
color coded red, indicating a problem area that should
preferably be discussed during the counseling session.
All other problem domains, are color coded green, indi-
cating that there is, in principle, no need to discuss it
during the counseling. Additionally, based on the litera-
ture and analysis of a validation of the DT in a previous
study by our group using a heterogeneous sample of
counselees for cancer in the Netherlands, a score of 4 or
greater on the DT is used to indicate a clinically relevant
level of distress [25,29]. Finally, the counselor will re-
ceive information about whether the counselee is inter-
ested in obtaining additional professional psychosocial
support for any given problem area. Scores on the DT
above the cut-off point, and counselees’ requests for
additional psychosocial support are also color coded red.
Additionally, to increase the ease of interpretation of the
results, all items above the threshold will be printed in a
bold font, and those items that are not above the thresh-
old will be printed in light-grey. All counselors willreceive written instructions/guidelines and training in
the use of the PAHC questionnaire and the DT.
Control group procedure
Counselees in the control group will complete the PAHC
questionnaire and DT as described above for the interven-
tion group. However, the results of these questionnaires
will not be provided to the genetic counselors.
Timing and content of study measures
Counselees will be asked to complete questionnaires at:
(1) baseline, prior to randomization; (2) approximately
4 weeks following the first genetic counseling session,
before the final counseling session takes place; and (3)
approximately 4 months after the telephone-based coun-
seling session.
The counselors will be asked to complete a baseline
questionnaire at the start of the study, a checklist at the
end of each counseling session, and a final questionnaire at
the end of the study. Both the in-person and the telephone-
based genetic counseling sessions will be audiotaped by
two independent raters (WE, GNS) for purposes of content
analysis (see below). Inter-rater reliability will be assessed
by double coding 10% of the audiotaped sessions, equally
divided between the intervention group and control group
sessions.
Sociodemographic and clinical data
The counselees’ age, gender, marital status, education level,
number and age of children, and use of psychosocial ser-
vices in the past and during the study, will be obtained via
the self-report questionnaires (Table 1). Data on whether
(s)he was diagnosed with cancer in the past and, if so, at
what age, whether there is a known gene mutation in the
family, the counselees’ genetic test results, and the number
of genetic counseling sessions will be extracted from the
medical records.
The counselors’ age, gender, and the number of years
working at the family cancer clinic will be determined by
questionnaire. (Table 1).
Primary outcome measures
The primary outcomes of the trial are: (1) discussion of
psychosocial problems; (2) counselors’ awareness of the
counselees’ psychosocial problems; and (3) management of
psychosocial problems during and after genetic counseling.
Discussion of psychosocial problems
Counselor-counselee communication about psychosocial
issues will be assessed via content analysis of the audio-
taped counseling sessions. Using a study-specific ques-
tionnaire, each counseling session will be coded for the
specific psychosocial issues discussed during the coun-
seling session. The coding reflects the 26 psychosocial
Table 1 Content and timing of study measures
Content of the measurement Timing of measurement
Counselees
Baseline (first) questionnaire Cancer worries Before randomization
General distress
Demographic data
Second questionnaire (T1) Evaluation of screening instrument 4 weeks after genetic counseling, before final consult, end of phase I
Evaluation of counselor
General distress
Need for extra support
Cancer worries
Third questionnaire (T2) Specific psychosocial problems 4 months after the telephone call,
Need for extra support end of phase II
Cancer worries




Checklist Counselors’ awareness After each counseling session and telephone call
Baseline questionnaire Demographic data Before the beginning of trial
First questionnaire Evaluation of screening instrument After finishing the trial
Counselees and counselors Audio tapes Genetic counseling
Telephone call, 4 weeks after DNA-test disclosure
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centage of counseling time devoted to the discussion of
psychosocial issues will be calculated.Counselors’ awareness
Counselors’ awareness of the psychosocial problems as ex-
perienced by their counselees will be assessed with a
checklist completed by the counselors directly after the
counseling sessions. The counselor will be asked to report
whether (s)he believes that the counselee is experiencing
problems in each of the 6 problem domains covered by
the PAHC questionnaire on a 4-point scale ranging from
(1, “no problem” to 4, “a severe problem”). The counselors’
ratings will be compared to the responses provided by the
counselees on the PAHC questionnaire.Management of psychosocial problems
The audiotapes of the counseling sessions will also be used
to evaluate how the counselees’ psychosocial problems are
managed. Specifically, the study-specific checklist will be
used to code whether counselees were referred to add-
itional sources of information about how to deal with psy-
chosocial problems (e.g., websites or written materials) or
to additional psychosocial counseling. The counselees will
be asked to report their actual use of psychosocial services.Secondary outcome measures:
Secondary outcomes include: (1) initiation of problem dis-
cussion; (2) the time devoted to discussing each psycho-
social problem and the total duration of the counseling
session; (3) cancer worries and general psychological dis-
tress; (4) cancer genetics-specific psychosocial problems;
and (5) counselees’ and counselors’ satisfaction with the
genetic counseling and with the intervention (the latter for
the intervention group only).Initiation of psychosocial issue discussion, and time devoted
to such discussions
The audiotapes of the counseling sessions will be coded for
who initiated the discussion of each specific psychosocial
issue (i.e., the counselee or the counselor), the amount of
time spent talking about psychosocial issues, and the total
length of the counseling session.Cancer worries and general psychological distress
Cancer worries will be assessed using an adapted version
of the Cancer Worry Scale (CWS) as used in previous
studies [14,15,30]. The CWS is an 8-item questionnaire
measuring the frequency of cancer worries, the impact
of worries on mood, and the impact of worries on daily
functioning.
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be used to assess general psychological distress [31]. The
HADS includes 14 questions and yields a total score, as
well as subscale scores for anxiety and depression. It has
been validated for use in the Netherlands [32].
Specific psychosocial problems
The PAHC questionnaire will be used to assess (changes
over time in) specific psychosocial problems experienced
by counselees in both the intervention and the control
group. This will be evaluated at both the individual item
as well as the problem domain level.
Satisfaction, evaluation and feasibility
Counselee and counselor satisfaction with both the genetic
counseling itself and with the intervention (the latter for
the intervention group only) will be assessed using an
adapted version as used in a study by Bleiker et al. [33].
Sample size and power calculations
We have based the sample size estimates on expected dif-
ferences between the intervention group and the control
group in communication between the genetic counselors
and counselees about psychosocial issues. Overall power
calculations for estimating sample size requirements were
based on the following criteria for defining a substantively
meaningful statistical association: (1) power of 0.80, (2)
alpha of 0.05, and an (3) effect size “d” of 0.4. With these
criteria, 99 cases per study arm are needed, resulting in a
total sample size of 198 cases.
We anticipate that approximately 25% of the coun-
selees will not have more than one counseling session
and thus will not have a DNA-test disclosure session.
Therefore, in order to have sufficient power in the sec-
ond phase of the trial, we will include 264 participants at
the start of the trial.
Statistical analyses
All analyses will be performed on an intention-to-treat
basis. Missing data on the HADS and CWS will be im-
puted using half-scale mean substitution methods. Data
of participants who complete and return their first
follow-up questionnaire after their final counseling ses-
sion will be omitted from the analysis, because knowing
the DNA-test result might influence questionnaire re-
sponses. Between rater agreement on the audiotaped
sessions will be assessed by calculating the percentage of
absolute agreement. Effect sizes will be calculated using
standard statistical approaches.
Non-participant analysis
Based on experience with other studies, we anticipate
that approximately 40% of eligible participants will de-
cline to participate in the study. The non-participantswill be compared with participants on available sociode-
mographic and clinical data using appropriate statistics
(e.g. Student’s t-test, or non-parametric test).
Comparability of intervention and control group
The comparability of the intervention and control groups
at baseline will first be evaluated in terms of sociodemo-
graphic and clinical characteristics. Student’s t-test or ap-
propriate non-parametric tests will be used. If, despite the
stratified randomization procedures, the groups are found
to be statistically different on one or more baseline charac-
teristics, these variables will be adjusted for in subsequent
analyses.
Main research hypotheses
We will evaluate group differences in the number of psy-
chosocial issues discussed during the genetic counseling
sessions using analysis of (co)variance. We will assess
counselors’ awareness of their counselees’ psychosocial
problems by calculating the agreement between coun-
selees’ and counselors’ on their ratings, per domain, of the
psychosocial problems experienced by the counselees. We
will calculate an Intraclass Correlation Coefficient (ICC2.1.
A [34]) per domain for both the intervention and control
group. Group differences will be assessed by treating the
ICC’s as Pearson correlation coefficients and using Fisher’s
r-to-z transformation to test for statistical differences per
domain. Analysis of (co)variance will also be used to evalu-
ate group differences in referral to additional information
sources and/or referral to psychosocial care services, and
the actual use of such services.
Secondary research hypotheses
We will employ analysis of (co)variance to evaluate group
differences in the frequency of with which the genetic
counselor initiated the discussion of psychosocial issues.
Analysis of (co)variance will also be used to evaluate group
differences in the amount of counseling time spent dis-
cussing psychosocial issues, and the total length of the
counseling session. To evaluate group differences in can-
cer worries and general distress, we will use analysis of co-
variance, with the previous scores on these questionnaires
as covariate. Logistic regression analysis will be used to
evaluate differences between groups in the prevalence of
cancer genetics-specific problems. Group differences in
satisfaction with the genetic counseling process will be ex-
amined with Student’s t-tests and chi square tests, where
appropriate. Intervention group and counselor satisfaction
with the intervention will be reported descriptively.
Discussion
Previous studies have shown that psychosocial problems
experienced by individuals undergoing genetic counseling
for cancer are often left undetected and thus untreated.
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is to make use of patient reported outcome (PRO) mea-
sures in routine clinical practice to first identify, and then
to manage relevant psychosocial issues. Previous studies
that have evaluated the efficacy of implementing PRO
measures in clinical settings have shown an increase in
communication about health-related issues and an in-
crease in clinicians’ awareness of their patients’ problems
and, to a lesser extent an improvement in patient manage-
ment and health over time [21-23,35]. To our knowledge,
no previous studies have investigated the value of using
such PRO data in daily clinical cancer genetic counseling.
This clinical trial will evaluate the efficacy of using a
relatively brief, psychosocial screening questionnaire, the
PAHC questionnaire, in improving communication about,
recognition of, and management of psychosocial problems
among individuals undergoing cancer genetic counseling
and testing.
Methodological issues
A major strength of the study is its use of a randomized
design that will ensure high levels of internal validity. The
relatively large sample size, the multicenter approach, and
the heterogeneity of the study sample will increase the ex-
ternal validity and generalizability of the findings.
Several possible limitations of the study should also be
noted. First, due to the nature of the intervention, it is not
possible to blind the genetic counselors, nor the coun-
selees, nor the raters of the audiotapes to group allocation.
This carries with it the risk of contamination, particularly
on the part of the counselors. That is, any given genetic
counselor will be seeing both counselees assigned to the
intervention group and the control group. Thus, it is con-
ceivable that the counselors’ experience with the interven-
tion (i.e., receiving personalized feedback regarding the
counselees’ self-reported psychosocial problems) will also
affect the way they interact with counselees in the conrol
group. We would note, however, that any such carry over
effect will have a conservative effect on the study (i.e., that,
if anything, it will make it more difficult to observe signifi-
cant group differences on the primary study outcomes). A
second possible limitation of the study will depend on the
observed prevalence of psychosocial problems among
counselees. If the prevalence is low, then it will be more
difficult to detect group differences in the various study
outcomes. Finally, due to funding limits, the follow-up
period for the second phase of the trial is relatively short
(only 4 months).
Conclusion
If proven efficacious, the introduction of a standardized
procedure for assessing the psychosocial problems and
needs of individuals undergoing cancer genetic counsel-
ing and testing will be a welcome addition to currentclinical practice. It will facilitate timely discussion, detec-
tion and treatment of psychosocial issues specific to the
cancer genetics setting. This is particularly important given
the fact that the number of requests for genetic counseling
is expected to continue to increase in the future. This will
place additional demands on the time and resources of
genetic counselors. Tools that facilitate early detection and
treatment, or referral of those with specific psychosocial
problems and concerns, are welcome.
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